 | Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Guggenheim to "Neutral"
marketbeat.com - February 22 at 7:34 AM |
| 3 Oversold Stocks That Could Bounce Back in a Hurry (ALNY)
marketbeat.com - September 23 at 1:26 PM |
 | Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Announce Earnings of -$1.73 Per Share
americanbankingnews.com - March 4 at 12:34 PM |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%
americanbankingnews.com - March 3 at 7:18 PM |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Neutral" Rating from Guggenheim
americanbankingnews.com - March 1 at 10:27 AM |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Guggenheim
americanbankingnews.com - February 22 at 8:49 AM |
 | Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 18 at 5:02 PM |
 | Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
msn.com - February 18 at 12:01 PM |
| Alnylam Pharmaceuticals' (ALNY) Hold Rating Reiterated at Royal Bank of Canada
americanbankingnews.com - February 15 at 12:56 AM |
| Barclays Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $196.00
americanbankingnews.com - February 12 at 10:09 AM |
|
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $235.00 at HC Wainwright
americanbankingnews.com - February 12 at 10:09 AM |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $180.00 at Needham & Company LLC
americanbankingnews.com - February 12 at 9:37 AM |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $206.00 at Morgan Stanley
americanbankingnews.com - February 12 at 9:37 AM |
| Citigroup Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) to Neutral
americanbankingnews.com - February 12 at 9:00 AM |
 | Alnylam Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 11 at 5:52 PM |
 | Recap: Alnylam Pharmaceuticals Q4 Earnings
benzinga.com - February 11 at 5:21 PM |
 | Alnylam's long history, and promising future, of innovation
bizjournals.com - February 11 at 5:21 PM |
 | Alnylam Pharmaceuticals Inc (ALNY) Q4 2020 Earnings Call Transcript
fool.com - February 11 at 1:49 PM |
 | Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
businesswire.com - February 11 at 12:20 PM |
| Alnylam Pharmaceuticals Q4 misses beat, provides 2021 guidance and updates on recent activity
seekingalpha.com - February 11 at 11:34 AM |
| Preview: Alnylam Pharmaceuticals's Earnings
benzinga.com - February 10 at 12:48 PM |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Could Be 36% Below Their Intrinsic Value Estimate
finance.yahoo.com - February 5 at 7:55 AM |
| Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - January 28 at 1:12 PM |
| Vir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again
finance.yahoo.com - January 27 at 12:00 PM |
 | First Week of September 17th Options Trading For Alnylam Pharmaceuticals (ALNY)
nasdaq.com - January 15 at 1:15 PM |
| Alnylam sets ambitious goal: Be among top 5 most-valuable biotechs by 2025
bizjournals.com - January 10 at 9:11 PM |
| Alnylam Launches "Alnylam P5x25" Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
finance.yahoo.com - January 10 at 4:10 PM |
| Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis Program
seekingalpha.com - January 8 at 6:42 PM |
| Alnylam Pharmaceuticals, Inc.: Alnylam Reports Positive Vutrisiran Data; Maintaining Our $150 Fair Value Estimate
finance.yahoo.com - January 8 at 3:38 AM |
| Alnylam: HELIOS-A Phase 3 Study Of Vutrisiran Met Primary And Secondary Endpoints - Quick Facts
nasdaq.com - January 7 at 12:28 PM |
|
| Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
finance.yahoo.com - January 7 at 7:27 AM |
 | Get Ready For Health Care Stocks to Go Wild. How to Play Them.
barrons.com - January 5 at 7:14 AM |
| Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:35 PM |
| Update: Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gained 52% In The Last Five Years
finance.yahoo.com - December 22 at 8:33 AM |
| Is ALNY A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 20 at 8:13 PM |
| Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
finance.yahoo.com - December 15 at 10:16 AM |
| Global Antisense & RNAi Therapeutics Market Report 2020-2030 Featuring GlaxoSmithKline, Sanofi, Gene Signal & Acuitas Therapeutics Among Others
benzinga.com - December 8 at 10:24 PM |
 | CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary
bloomberg.com - December 8 at 5:23 PM |
| Alnylam to Webcast Virtual R&D Day
finance.yahoo.com - December 8 at 12:23 PM |
| Regeneron Pharmaceuticals, Inc. (REGN) Management Presents on Investor Event ASH 2020 Conference Call Transcript
seekingalpha.com - December 8 at 1:27 AM |
| Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company's Approved Therapies
benzinga.com - December 7 at 9:41 AM |
| Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
finance.yahoo.com - December 7 at 9:41 AM |
| Why Is Alnylam (ALNY) Down 6% Since Last Earnings Report?
finance.yahoo.com - December 5 at 4:07 PM |
| Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
finance.yahoo.com - December 3 at 6:11 PM |
| Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)
finance.yahoo.com - December 3 at 6:11 PM |
| PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
finance.yahoo.com - December 3 at 6:11 PM |
| Alnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNY
nasdaq.com - December 1 at 5:29 PM |
| 3 Reasons Alnylam Is a Top Biotech Stock to Buy Right Now
nasdaq.com - November 30 at 4:44 PM |
| Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
finance.yahoo.com - November 25 at 2:18 PM |
| Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
finance.yahoo.com - November 25 at 9:17 AM |
| Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra ...
businesswire.com - November 24 at 8:31 AM |
| FDA Approves Alnylam's Oxlumo To Treat Rare Metabolic Disorder
nasdaq.com - November 24 at 8:31 AM |
